Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov site as revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-31T13:25:35.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A banner announces an NIH-wide transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T18:50:37.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T20:47:13.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T20:56:30.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content with a generic error page; this change blocks access to the study's details and related sections.
    Difference
    16%
    Check dated 2026-09-19T20:11:21.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page shows Revision: v3.6.6, replacing v3.6.5, indicating a small maintenance update with no changes to the study details.
    Difference
    0.1%
    Check dated 2026-08-29T20:10:19.000Z thumbnail image

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.